Techno Time

PureHealth Shareholders Approve AED 600 Million Cash Dividend Following Robust 2025 Financial Performance

Tuesday 7 April 2026 09:07
PureHealth Shareholders Approve AED 600 Million Cash Dividend Following Robust 2025 Financial Performance

PureHealth Holding PJSC, the largest healthcare platform in the Middle East, announced today that its shareholders have approved a cash dividend distribution of AED 600 million for the fiscal year ended December 31, 2025.

​The decision, finalized during the company’s Annual General Meeting (AGM) held on April 2, 2026, represents approximately 30% of the group’s net profit. The payout underscores PureHealth’s strong financial trajectory and its commitment to delivering sustainable value to its investors.

​Dividend Payout Schedule

The AED 600 million dividend will be disbursed in two equal installments of AED 300 million each. According to the board’s resolution, the first payment is scheduled for completion by May 2, 2026, with the second installment following by August 31, 2026.

​Record-Breaking Financial Results

The dividend approval follows a year of significant growth for the group. PureHealth reported a total revenue of AED 27.3 billion for FY 2025, marking a 5.7% increase year-on-year. Other financial highlights include:

​EBITDA: Rose by 16.1% to reach AED 4.8 billion.

​Net Profit: Surged by 17.7% to AED 2.0 billion.

​This growth was primarily driven by the expansion of the group's healthcare and insurance sectors, alongside strategic international acquisitions, most notably the integration of Hellenic Healthcare Group.

​Strategic Vision

Shaista Asif, Group Chief Executive Officer of PureHealth, highlighted the company’s focus on innovation and global expansion.

"2025 was a year of strong performance that reflects the resilience and scalability of our integrated platform," Asif said. "As we continue to expand our global footprint and leverage data and Artificial Intelligence, we are building a more connected and proactive healthcare ecosystem. Our focus remains on improving patient outcomes and longevity while creating long-term value for our shareholders."

​The group continues to position itself as a leader in health-tech and longevity, utilizing advanced technology to shift the healthcare paradigm from reactive treatment to proactive wellness.